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ABSTRACT
Objectives: To evaluate the optimal lipid to measure
in monitoring patients, we assessed three factors that
influence the choice of monitoring tests: (1) clinical
validity; (2) responsiveness to therapy changes and
(3) the size of the long-term ‘signal-to-noise’ ratio.
Design: Longitudinal analyses of repeated lipid
measurement over 5 years.
Setting: Subsidiary analysis of a Long-Term Intervention
with Pravastatin in Ischaemic Disease (LIPID) study—a
clinical trial in Australia, New Zealand and Finland.
Participants: 9014 patients aged 31–75 years with
previous acute coronary syndromes.
Interventions: Patients were randomly assigned to
40 mg daily pravastatin or placebo.
Primary and secondary outcome measures:We
used data on serial lipid measurements—at
randomisation, 6 months and 12 months, and then
annually to 5 years—of total cholesterol; low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol and their ratios; triglycerides; and
apolipoproteins A and B and their ratio and their ability to
predict coronary events.
Results: All the lipid measures were statistically
significantly associated with future coronary events, but
the associations between each of the three ratio measures
(total or LDL cholesterol to HDL cholesterol, and
apolipoprotein B to apolipoprotein A1) and the time to a
coronary event were better than those for any of the single
lipid measures. The two cholesterol ratios also ranked
highly for the long-term signal-to-noise ratios. However,
LDL cholesterol and non-HDL cholesterol showed the
most responsiveness to treatment change.
Conclusions: Lipid monitoring is increasingly common,
but current guidelines vary. No single measure was best
on all three criteria. Total cholesterol did not rank highly on
any single criterion. However, measurements based on
cholesterol subfractions—non-HDL cholesterol (total
cholesterol minus HDL cholesterol) and the two ratios—
appeared superior to total cholesterol or any of the
apolipoprotein options. Guidelines should consider using
non-HDL cholesterol or a ratio measure for initial treatment
decisions and subsequent monitoring.
Since the marketing of 3-hydroxy-3-methyl-glu-
taryl-coenzyme A (HMG-CoA) reductase inhi-
bitors, lipid measurement workloads have
increased markedly.1 Much of this testing
appears to be for monitoring rather than
screening. However, it may be unnecessary: an
analysis of the Long-term Intervention with
Pravastatin in Ischaemic Disease (LIPID) trial2
suggested that 3–5 yearly monitoring may be
sufﬁcient for patients in good control.
Subsequent work in a primary prevention
population in Japan found that similar inter-
vals were adequate for untreated patients, but
also suggested that ratio measures (choles-
terol/high-density lipoprotein (HDL) or low-
density lipoprotein (LDL)/HDL cholesterol)
were superior as monitoring tests.3
Apolipoproteins are a further option for moni-
toring, either as a single measure or as a ratio
of apolipoprotein B/A1. With widening indica-
tions and use of cholesterol-modifying treat-
ment, it is timely to re-examine the most
appropriate lipid measurements for monitor-
ing purposes.
The methods and targets for monitoring
have incrementally changed over the past
two decades. Early guidelines focused on
total cholesterol for screening, as a target,
Strengths and limitations of this study
▪ This study had a large randomised cohort of
patients with good adherence and long
follow-up. There was some crossover of patients
during the trial, but if the crossover effects have
equal impact on all lipid measures, the relative
rankings should remain the same.
▪ Assessment of response to changes in treatment
used the initial and fixed treatment dose, rather
than dose titration. This assumes that detectabil-
ity of any titration of treatment is similar to the
detection of the initial treatment threshold, which
may not be true if the dose–response curves are
different for the different lipid measures.
▪ The relationships between lipid changes and out-
comes appear consistent across statins, but the
rankings may not hold exactly for other statins
or other lipid treatments such as fibrates.
▪ The conclusions need to be replicated in other
data sets.
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and for monitoring. However, the shift to assessment of
absolute cardiovascular disease risk and the better pre-
dictive ability of lipid ratios (total /HDL cholesterol or
LDL /HDL cholesterol) has led to a move to measure
and use a combination of HDL cholesterol and total
cholesterol or LDL cholesterol for screening and moni-
toring.4 5 The National Institute of Health and Care
Excellence (NICE) 2008 guideline6 pointed out: “Both
HDL cholesterol and total cholesterol form integral
aspects of the Framingham, QRISK (QRESEACH
Cardiovascular Risk Assessment Calculator) and ASSIGN
(ASSessing cardiovascular risk using SIGN—Scottish
Intercollegiate Guidelines Network) equations,” but sug-
gested that LDL cholesterol measurement is not
required for risk assessment. LDL cholesterol measure-
ment is also complicated by the need for specialist assays
to measure it directly or the analysis of a fasting sample
to allow indirect calculation (using the Friedwald equa-
tion).7 The National Cholesterol Education Program
guidelines for the USA recommend a 6-monthly moni-
toring of LDL cholesterol, as do the Australian guide-
lines of the National Heart Foundation and Cardiac
Society.8 In addition, apolipoprotein B and non-HDL
cholesterol can be obtained from fasting or non-fasting
samples, but apolipoprotein B also allows a measure of
the total number of atherogenic lipoprotein particles,
which is particularly important in people with diabetes
and the metabolic syndrome.9
Selection of an optimal monitoring measure should
be based on a consideration of three technical factors:
(1) clinical validity, that is, how well the measure is asso-
ciated with cardiovascular outcomes; (2) responsiveness
to therapy changes, that is, how clearly and rapidly the
measurement responds to new or changed treatment;
(3) a large “signal-to-noise” ratio to identify real changes
from background within-patient variability (‘noise’) and
a non-technical factor, (4) practicality, including costs,
clinicians’ familiarity and interpretability, access to the
test and the speed of results (including whether it is
available as a near-patient test).10
We therefore aimed to examine the three technical
factors for the potential lipid measurements for long-term
monitoring: total, LDL, HDL and non-HDL cholesterol,
the cholesterol ratios, and apolipoproteins (A1 and B),
and ratios.
METHODS
Data from the LIPID trial were analysed. In LIPID, 9014
patients from Australia, New Zealand and Finland, aged
31–75 years, who had had acute myocardial infarction or
hospitalisation for unstable angina 3–36 months previ-
ously and total cholesterol 4–7 mmol/L, were rando-
mised to 40 mg of pravastatin (4512 patients) or
matching placebo (4502) and followed up for an average
of 6 years.2 The trial included 6 monthly cholesterol
measurement, as well as information on compliance to
assigned therapy and ‘drop-in’ to other cholesterol-
modifying therapy. LDL cholesterol was estimated by
using the Friedwald equation, and patients with fasting
serum triglycerides >4.5 mmol/L (445 mg/dL) were
excluded from the study. The prespeciﬁed primary
outcome for subgroup analysis was death from coronary
heart disease (CHD) or non-fatal myocardial infarction
and that outcome has been used here. Deaths from CHD
were further classiﬁed as death due to fatal myocardial
infarction, sudden death, death in the hospital after pos-
sible myocardial infarction, or death due to heart failure
or another coronary cause.
Clinical validity was assessed by examining the associ-
ation of each measure with occurrence of coronary
events (CHD death and non-fatal infarction, as was pre-
speciﬁed as the primary outcome for subsidiary analyses
in the protocol) in all patients over 5 years of follow-up.
This built on a previous analysis of the LIPID study,11
which estimated the HR for such events per unit
change. However, the HRs are expressed in the arbitrary
units of their measurement, and do not account for
population prevalence or spread. Hence, to account for
the range in the population, and to make the measures
comparable, we calculated the HR from measures in the
interquartile range (IQR).
Responsiveness to change in therapy was assessed by
two methods. First, we estimated the proportional
change in response to initiation of pravastatin treatment;
if the lipid measure had clinical validity, then the pro-
portional change would be a good surrogate measure of
treatment response. Second, we divided this propor-
tional change by the short-term variability (‘noise’) in
the particular measure.12 This was equivalent to estimat-
ing the ratio of the percentage change to the coefﬁcient
of variation, and was a standardised measure of the
maximum potential variability in response. However, it
was not a direct measure of the between-person variabil-
ity in response and might appear substantial even when
all patients had the same response to treatment.
Short-term variability, which involves multiple factors
including assay variability, diurnal variation, short-term
variation in diet or physical activity, etc, was estimated by
two methods. The ﬁrst used assays during the run-in
period (excluding the ﬁrst measurement), which were
taken only a few weeks apart. Second, because of the
possible short-term correlation, this result was checked
with linear extrapolation backwards from the longer-
term measures, to establish what the apparent variance
at time 0 would be (this method is known as a
‘variogram’).
To estimate the detectability of long-term changes
(the signal-to-noise), we needed to estimate the long-
term variability (the ‘signal’) and compare this with the
short-term variability (the ‘noise’: see previous para-
graph). The long-term variability was derived from the
average squared difference of the measure compared
with the baseline, that is (measure at timei−measure at
time0)
2, where timei is the 6-month, 12-month or
18-month time point. The within-person variability for
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each of the different periods is half the variance of this
difference. By subtracting the short-term variability from
the long-term variability, the ‘random drift’ with time
could then be estimated, and hence the likelihood of a
patient’s ‘true’ measure having drifted beyond the
upper or lower boundaries around the target.
As the aim was to estimate change in those on stable
treatment, a key issue was coping with the patients who
dropped into or dropped out of treatment. Hence,
when patients dropped in to cholesterol-modifying medi-
cation, they remained in the analysis but the data were
‘truncated’, and values were thereafter replaced with an
imputed value (eg, the last value carried forward).
CIs based on the 2.5th centile to the 97.5th centile
from 2000 bootstrap estimates of each of the measures
are provided.13
RESULTS
Clinical validity
Among all patients, 12.3% (557) of those assigned pravas-
tatin and 15.9% (715) assigned placebo had a major CHD
event during follow-up. Among the 4231 patients assigned
placebo who had all baseline lipid measures, there were
664 events; all the lipid measures showed a statistically sig-
niﬁcant association with future coronary events (table 1).
All had positive HRs except HDL cholesterol and apo-
lipoproteins B and A1, which were negative (protective).
The HR per unit (column 1) depends on the units
used. To compare the different measures, the HR from
the upper to the lower quartile was calculated (ﬁnal
column; also see table 2). On this scale, the association
with CHD events of the three ratio measures (total or
LDL cholesterol to HDL cholesterol, and apolipoprotein
A1 to B) was better than any of the single measures. For
example, for LDL cholesterol the hazard increases by
15% between the lower and upper quartile, whereas for
the LDL/HDL cholesterol the hazard increases 30%
from the lower to upper quartile. Similarly, the apolipo-
protein B/A1 ratio was better than either of the apolipo-
proteins alone. Thus, the ratios appeared more strongly
associated with coronary events during the study than
single measures.
Responsiveness to therapy changes
The responsiveness to change in therapy is ideally mea-
sured by examining the size and variation in responses
Table 2 25th and 75th centiles and IQR for baseline lipid measurement in the placebo group, corresponding to table 1
Lipid 25th centile 75th centile Difference (IQR)
Total cholesterol (mmol/L) 5.08 6.20 1.12
LDL cholesterol (mmol/L) 3.40 4.41 1.01
HDL cholesterol (mmol/L) 0.79 1.09 0.30
Total to HDL cholesterol ratio 1.18 2.12 0.94
LDL to HDL cholesterol ratio 1.17 1.45 0.28
Non-HDL cholesterol (mmol/L)* 1.16 1.49 0.33
Triglycerides (mmol/L) 5.12 7.14 2.02
Apolipoprotein A1 (g/L) 3.45 4.98 1.53
Apolipoprotein B (g/L) 0.86 1.20 0.34
Apolipoprotein B/A1 4.14 5.24 1.10
*Total minus HDL cholesterol.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 1 Clinical validity for prediction of coronary heart disease death or non-fatal myocardial infarction, in 4502 patients
randomised to the placebo group*
Lipid HR per unit (95% CI) p Value HR (95% CI) over IQR* Rank†
Total cholesterol (mmol/L) 1.12 (1.02 to 1.23) 0.02 1.13 (1.02 to 1.26) 9
LDL cholesterol (mmol/L) 1.15 (1.04 to 1.27) 0.01 1.15 (1.04 to 1.28) 8
HDL cholesterol (mmol/L) 0.53 (0.37 to 0.74) 0.001 1/1.20 (0.74 to 0.92) 5
Total to HDL cholesterol ratio 1.14 (1.08 to 1.19) 0.001 1.29 (1.17 to 1.42) 2
LDL to HDL cholesterol ratio 1.19 (1.12 to 1.27) 0.001 1.30 (1.18 to 1.43) 1
Non-HDL cholesterol (mmol/L)‡ 1.18 (1.08 to 1.30) 0.001 1.20 (1.09 to 1.34) 5
Triglycerides (mmol/L) 1.07 (0.99 to 1.16) 0.09 1.07 (0.99 to 1.15) 10
Apolipoprotein A1 (g/L) 0.48 (0.34 to 0.70) 0.001 1/1.22 (0.74 to 0.90) 4
Apolipoprotein B (g/L) 1.64 (1.21 to 2.21) 0.001 1.18 (1.06 to .130) 7
Apolipoprotein B/A1 2.05 (1.54 to 2.73) 0.001 1.28 (1.16 to 1.41) 3
*Data derived from Simes and coauthors.12
†Rank is based on the predictive power irrespective of direction: higher HDL and apolipoprotein A are protective.
‡Total minus HDL cholesterol.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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to up-titration or down-titration of long-term therapy
through changes in dose or additions of medications.
However, in the LIPID trial, patients were all maintained
on a ﬁxed dose of therapy for the duration of the study.
Hence, the size and variation in response to initial
therapy were examined as a surrogate for responsiveness
to ongoing titration. The changes in 4512 patients ran-
domised to pravastatin are consistent with known
responses to statins, demonstrating a substantial decrease
in total cholesterol and LDL cholesterol, and a small
increase in HDL cholesterol (table 3). LDL cholesterol
ranks highly on the percentage change and the ratio of
percentage change to the coefﬁcient of variation.
Ideally, these results would be supplemented by a similar
analysis of the effects of a further titration step, for
example, increasing the dose or adding additional
cholesterol-modifying medication.
Large signal-to-noise ratio
The ratios of signal-to-noise (table 4) were best for the
ratio measures, with only total/HDL cholesterol and
LDL /HDL cholesterol exceeding 1 after 3 years. The
values in table 4 are for the 4502 patients in the placebo
group, as this allows the signal to be estimated from the
baseline rather than in later follow-up when the effect of
statin treatment has become stable. However, the
signal-to-noise results were similar when the shorter
follow-up available for the (not presented) statin-treated
group was examined.
Summary rankings
Judged by rankings (table 5), no single measurement
was best for all three criteria. However, total cholesterol
did not rank highly on any of the criteria, although the
measures based on cholesterol subfractions did rank
highly. None of the measures based on apolipoproteins
ranked particularly well, though the ratio of apolipopro-
tein A1–B performed best.
DISCUSSION
On the three criteria of clinical validity, responsiveness
to treatment changes and detectability of long-term
changes, differences between the potential lipid mea-
sures were substantial. No single measure was best on all
three criteria. Total cholesterol did not rank highly on
any single criterion. However, measurements based on
cholesterol subfractions—the two ratios and non-HDL
cholesterol (total minus HDL cholesterol)—appeared
superior to either total cholesterol or any of the apolipo-
protein options.
The ﬁndings for the separate criteria are generally
consistent with previous studies. For initial risk measure-
ment, there is evidence from cohort studies14–16 and a
meta-analysis17 to suggest that lipid ratios (total/HDL
cholesterol and LDL/HDL cholesterol) have higher
associations with CHD than individual serum total or
LDL cholesterol levels. The results for the third criteria
were similar to those of a study of a primary-prevention
population in Japan, which showed that lipid ratios have
larger signal-to-noise ratios than single standard lipids
(1.6 for total/HDL cholesterol and 1.5 for LDL/HDL
cholesterol compared with 0.8 for total cholesterol and
0.99 for LDL cholesterol).3
Although this study had a large randomised cohort of
patients with good adherence and long follow-up, there
are some limitations. First, there was some crossover,
both dropout from and drop-in to treatment, of patients
during the trial, which will inﬂuence the assessment of
clinical validity and the signal-to-noise ratios. However, if
the crossover effects have equal impact on all lipid mea-
sures, then the relative rankings should remain the
same. Another limitation is our assessment of response
to changes in treatment, which used the initial and ﬁxed
Table 3 The absolute and percentage change in lipids in response to initial statin treatment compared with the coefficient of
variation, in 4512 patients randomised to pravastatin
Lipid Change Change (%) Rank
Variation
(coefficient
of variation) (%)
Change/coefficient
of variation (%) Rank*
Total cholesterol (mmol/L) 1.16 21 7 0.30 (10) 2.13 (2.11, 2.19) 3
LDL cholesterol (mmol/L) 1.09 28 2 0.25 (28) 2.20 (2.16, 2.24 1
HDL cholesterol (mmol/L) −0.04 −4 10 0.01 (11) −0.35 (−0.38, −0.33) 10
Total to HDL cholesterol ratio 1.40 23 5 1.46 (20) 1.81 (1.78–1.84) 7
LDL to HDL cholesterol ratio 1.29 30 1 0.73 (20) 1.95 (1.92–1.99) 5
Non-HDL cholesterol (mmol/L)† 1.18 25 4 0.29 (11) 2.20 (2.14, 2.21) 1
Triglycerides (mmol/L) 0.19 11 8 0.27 (29) 0.37 (0.35, 0.40) 9
Apolipoprotein A1 (g/L) −0.07 6 9 0.014 (9) −0.62 (−0.66, −0.60) 8
Apolipoprotein B (g/L) 0.29 22 6 0.02 (12) 1.86 (1.83, 1.91) 6
Apolipoprotein B/A1 0.27 26 3 0.02 (13) 2.01 (1.98, 2.04) 4
*Rank is based on the absolute size of the change/coefficient of variation, irrespective of direction.
†Total minus HDL cholesterol.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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treatment dose, rather than dose titration. This assumes
that detectability of any titration of treatment is similar
to the detection of the initial treatment threshold. This
may not be true if the dose–response curves are differ-
ent for the different lipid measures. Related to this
assumption is our use of a single large trial of pravasta-
tin. While the relationship between lipid changes and
outcomes appears consistent across statins,18 the rank-
ings here may not hold exactly for other statins, and less
so for other lipid treatments such as ﬁbrates.
In addition to the need for replication in other popu-
lations and with other agents, there are some other
limitations of our analyses. While the three technical cri-
teria—clinical validity, responsiveness and good
‘signal-to-noise’—are appropriate, many options to
measure each are possible. For example, we assessed the
predictive validity of the measures at baseline, but could
also have assessed the predictive validity of the change
values; similarly, while we used responsiveness to initial
treatment as the measure, responsiveness in titration
might be clinically more relevant, but would be more
difﬁcult to measure and less discriminating. In
generalising these results to different populations and
different agents, the assumption would be that while the
exact values such as changes and CVs would be differ-
ent, the rankings would remain the same. For example,
the IQRs used for the clinical validity measure are likely
to be larger in other populations (as LIPID had a
restricted range), but if these increases in IQR were pro-
portionately equal, then the rankings would be pre-
served. However, these assumptions, while not
unreasonable, need to be tested in these other popula-
tions and agents.
The main implication of these results is that total choles-
terol, based on the three technical criteria, is not the
‘optimal’ measurement for monitoring statin treatment.
While LDL cholesterol is somewhat better, it was still low in
the rankings. The most promising and practical measure-
ment would appear to be either the non-HDL cholesterol
or the LDL/HDL cholesterol ratio. The ratios (LDL /HDL
cholesterol or total/HDL cholesterol) have the advantage
of being widely used currently for the initial assessment of
cardiovascular risk, with total/HDL cholesterol having the
practical advantage of not needing LDL measurement.
Table 4 Signal-to-noise ratios at 1 and 3 years (change from placebo group; CV from all patients)
Lipid Signal Noise Signal-to-noise ratio
Rank
Change from
year 0
CV
Change/CV
Year 1 Year 3 Year 1 Year 3
Total cholesterol (mmol/L) 0.13 0.24 0.30 (10) 0.43 (0.38–0.51) 0.80 (0.73–0.89) 8
LDL cholesterol (mmol/L) 0.08 0.17 0.25 (13) 0.31 (0.26–0.39) 0.70 (0.61–0.78) 10
HDL cholesterol (mmol/L) 0.01 0.01 0.013 (12) 0.54 (0.44–0.63) 0.97 (0.85–1.09) 3
Total to HDL cholesterol ratio 0.37 0.86 0.63 (13) 0.59 (0.53–0.70) 1.37 (1.31–1.50) 1
LDL to HDL cholesterol ratio 0.22 0.54 0.42 (15) 0.53 (0.46–0.64) 1.29 (1.25–1.47) 2
Non-HDL cholesterol (mmol/L) 0.14 0.22 0.27 (11) 0.52 (0.45–0.70) 0.82 (0.73–0.89) 6
Triglycerides (mmol/L) 0.23 0.42 0.37 (34) 0.37 (0.29–0.53) 0.88 (0.73–0.89) 5
Apolipoprotein A1 (g/L) 0.01 0.02 0.02 (11) 0.33 (0.28–0.39) 0.77 (0.68–0.86) 9
Apolipoprotein B (g/L) 0.01 0.02 0.03 (12) 0.52 (0.38–0.62) 0.82 (0.69–0.93) 6
Apolipoprotein B/A1 0.01 0.01 0.02 (13) 0.45 (0.37–0.58) 0.89 (0.77–1.08) 4
CV, coefficient of variation; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 5 Summary of ranking of lipid measurements for three criteria: clinical validity; response to therapy changes and
long-term signal-to-noise ratio
Lipid measurement Validity Change (%)
Change/coefficient
of variation (%)
Long-term
signal-to-noise
Total cholesterol 9 7 3 8
LDL cholesterol 8 2 1 10
HDL cholesterol 5 10 10 3
Total to HDL cholesterol ratio 2 5 7 1
LDL to HDL cholesterol ratio 1 1 5 2
Non-HDL cholesterol 5 4 1 6
Triglycerides 10 8 9 5
Apolipoprotein A1 4 9 8 9
Apolipoprotein B 7 6 6 6
Apolipoprotein B/A1 3 3 4 4
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Using a ratio for monitoring would then mean that the
same measure was being used for initial and subsequent
measurement and would simplify guidelines and the
numbers that clinicians and patients would need to know.
One problem, however, is the instability of ratios in patients
with very low HDL cholesterol. This latter problem does
not occur with non-HDL cholesterol, which has several
other advantages: it also appears to do well on most of the
criteria; it does not require LDL measurement (direct or
indirect); and it is readily available or can be easily calcu-
lated from current laboratory reports.
Our analysis suggests that, based on the three technical cri-
teria, a cholesterol difference (non-HDL cholesterol) or ratio
(LDL/HDL cholesterol) is preferable as lipid-monitoring
measurements for patients taking statins (the issue of detect-
ing non-compliance by monitoring was not considered, and
has been analysed elsewhere).19 However, the fourth criter-
ion—practicality—will clearly also inﬂuence this choice:
non-HDL is feasible and robust but less familiar to clinicians,
whereas the ratios are more familiar but rely on an accurate
LDL measurement and automated calculations carried out
by laboratories. Furthermore, our conclusions are based on a
single study in patients with established CHD and need to be
replicated in other data sets. These should include assess-
ment of the measures during treatment with cholesterol-
modifying therapies other than HMG-CoA reductase inhibi-
tors, which might have different effects on lipid parameters.
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